Cassava Sciences Inc vs 10X Genomics Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while 10X Genomics Inc trades at $58.72 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 159.4× Cassava Sciences Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TXG | |
|---|---|---|
Market Cap | $47.75M | $7.61B |
Sector | Health | Health |
52-Week High | $4.64 | $58.57 |
52-Week Low | $0.87 | $11.34 |
Enterprise Value | -$34.93M | $7.14B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →